Abstract:Khalid Altigani Ahmed, 1 Alnada Ibrahim, 2 Daniel Gonzalez, 3 Abubakr O Nur 4 1 Department of Clinical Pharmacy, College of Pharmacy, Najran University, Najran, Saudi Arabia; 2 Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia; 3 Division of Clinical Pharmacology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; 4 Department of Pharmaceutics, Faculty of Pharmacy, University of Khartoum, Khartoum, Sudan Correspondence: Alnada Ibrahim, Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh, 11671, Saudi Arabia, Email Purpose: The study aimed to perform a population pharmacokinetic (PK) analysis to obtain vancomycin PK parameter estimates in Sudanese adult patients. The population PK model is then applied to perform model-based dose optimization. Patients and Methods: Data were collected through a retrospective, single-center, observational cohort study performed in Aliaa Specialist Hospital, Khartoum, Sudan. A population PK model was developed using the MonolixSuite 2020R1 to explore the potential effects of demographics and laboratory covariates on vancomycin PK. Monte Carlo simulations were performed to optimize dosage regimens as a function of creatinine clearance (CLcr) and virtual patients were partitioned into five CLcr groups. Results: We retrospectively collected 194 vancomycin plasma concentrations from 99 adults. The median (interquartile range) for age (years) and CLcr (mL/min) were 65 (50– 75) and 12.7 (5.52– 25.78), respectively. Vancomycin PK data were best fitted using a one-compartment model with linear elimination. The estimates of clearance and volume of distribution were 2.02 L/h and 65 L, respectively. CLcr was identified as the main covariate explaining the PK variability in vancomycin CL. CL significantly decreased with decreasing CLcr. For the five CLcr groups evaluated, a tailored vancomycin daily maintenance dose (using patients' CLcr) ranged from 200 to 1650 mg. Overall, simulations showed that 45% (CI; 41.11– 47.36%) of patients would achieve a target AUC with the suggested dosages. Conclusion: A population PK model of vancomycin was developed using data obtained from adult Sudanese patients. Model-based dose optimization can aid clinicians in selecting initial vancomycin doses that will maximize the likelihood of a favorable treatment response. Keywords: vancomycin, dose individualization, monitoring, pharmacokinetics dosing, pharmacometrics Vancomycin is a first-line therapy for methicillin-resistant Staphylococcus aureus (MRSA), and therapeutic drug monitoring (TDM) is performed to reduce the risk of nephrotoxicity and assure optimal therapeutic outcomes. Several organizations have produced clinical practice recommendations to guide TDM of vancomycin. 1,2 The minimum inhibitory concentration (MIC) of vancomycin against MRSA continues to rise due to its extensive use. 3 On the other hand, vancomycin's pharmacokinetic (PK) parameters have wide variability among the different patient populations that receive the drug. 4,5 Therefore, dose individualization based on MIC and patient-specific factors is essential to achieving an optimal outcome. Vancomycin is primarily eliminated through renal elimination, and its clearance (CL) is closely linked to creatinine clearance (CLcr). As a result, the main source of vancomycin PK parameter fluctuations is renal function. 6 Vancomycin PK parameters have a wide range of values. According to a review paper on vancomycin population PK studies in adult patients, the typical values of vancomycin CL ranged from 0.334 to 8.75 L/h. The volume of distribution (V) ranged from 7.12 to 154 L and 29.2 to 501.8 L in the case of one- and two-compartment models, respectively. The between-subject variability (BSV) was reported to be as high as 77% for V and 99% for CL. 7 Recent guidelines recommend targeting an area under the concentration vs time curve (AUC)/minimum inhibitory concentration (MIC) ratio of 400 to 600 (assuming an MIC of 1 mg/L) for empiric dosing in both adult and pediatric patients to maximize clinical efficacy and minimize acute kidney injury (AKI) risk. 2 Population PK modeling and simulation have helped identify the optimal dosing of vancomycin by assessing the inter- and intra-subject variability in PK. Previous studies reported that vancomycin trough concentrations and race were risk factors of vancomycin-related AKI, among other risk factors. 8–10 Hence, the importance of vancomycin trough level and renal function close monitoring was highlig -Abstract Truncated-

Vancomycin loading dose individualization in a population of obese patients undergoing haemodialysis based on population pharmacokinetic model

Population Pharmacokinetics of Vancomycin in Kidney Transplant Recipients: Model Building and Parameter Optimization.

Vancomycin population pharmacokinetics and dosing proposal for the initial treatment in obese adult patients

Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals

Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations

Initial Dosage Regimens Of Vancomycin For Chinese Adult Patients Based On Population Pharmacokinetic Analysis

Review and evaluation of vancomycin dosing guidelines for obese individuals

Pharmacokinetics of Vancomycin in Healthy Korean Volunteers and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients with Normal Renal Function

External evaluation of intravenous vancomycin population pharmacokinetic models in adults receiving high‐flux intermittent haemodialysis

Population Pharmacokinetics and Model-Based Dose Optimization of Vancomycin in Sudanese Adult Patients with Renal Impairment

Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients

Vancomycin population pharmacokinetic models: Uncovering pharmacodynamic divergence amid clinicobiological resemblance

Population pharmacokinetics and individualized dosing of vancomycin for critically ill patients receiving continuous renal replacement therapy: the role of residual diuresis

Individualized medication model of vancomycin in patients with renal insufficiency using machine learning techniques

Population pharmacokinetics and dosing optimization of vancomycin in infants, children and adolescents with augmented renal clearance

Dose Optimization of Vancomycin for Critically Ill Patients Undergoing CVVH: A Prospective Population PK/PD Analysis

Population pharmacokinetic analysis for dose regimen optimization of vancomycin in Southern Chinese children

Determination of vancomycin exposure target and individualized dosing recommendations for critically ill patients undergoing continuous renal replacement therapy

Population Pharmacokinetic Modeling and Dose Optimization of Vancomycin in Chinese Patients with Augmented Renal Clearance

Vancomycin Population Pharmacokinetic Modeling in Children Using Bayesian Estimation and a Non Parametric Approach

Weight-based Vancomycin Loading Strategy May Not Improve Achievement of Optimal Vancomycin Concentration in Patients with Preserved Renal Function